EVENT SPEAKERS:

- **Jim Dowling**  
  MD, PhD, FRCP  
  SickKids Hospital

- **Hugh McMillan**  
  MD, MSc, FRCP, FAAN  
  Montreal Children’s Hospital

- **Pranesh Chakraborty**  
  MD, FRCP, FRCMG  
  Children’s Hospital of Eastern Ontario

- **Stacey Lintern**  
  CEO  
  Muscular Dystrophy Canada

- **Homira Osman, PhD**  
  VP  
  Research and Public Policy  
  Muscular Dystrophy Canada

Join us for this innovative virtual CNSF 2021 symposium that will review current and emerging gene therapy research for the treatment of paediatric neuromuscular diseases.

**December 2, 2021 7:00 PM (EST)**

Through expert presentations, participants will learn about exciting advances in gene therapy for the treatment of neuromuscular diseases, including SMA. Speakers will also explore the critical role newborn screening plays in facilitating pre-symptomatic diagnosis and early treatment of disease, and the implementation of newborn screening in Canada. The session will then be followed by an interactive live Question & Answer session with all speakers.

**CLICK HERE TO REGISTER**

**PROGRAM OBJECTIVES:**

Upon completion of this program, participants will be better able to:

- Discuss the current clinical research evidence and application of gene therapy in paediatric neurological and neuromuscular diseases (NMD)
- Appraise the role of current treatments in helping SMA patients reach their milestones
- Summarize the key considerations, learnings and outcomes related to public and private sectors working on newborn screening (NBS)
- Determine the role of the clinical and research community in facilitating the inclusion of additional NMDs’ into NBS

**CLICK HERE TO REGISTER**

For any questions about the event, contact mhtherrien@medplan.ca.